

Short Research Article

Knowledge Level and Perceptions of Pharmacists and Prescribers Regarding Boxed Warnings

Background: Black box warnings indicating harmful or potentially fatal adverse events are required by the Food and Drug Administration on certain drugs and chemical entities; however it is unclear if prescribing and dispensing habits are impacted by these warnings. This study investigates the knowledge and perceptions of prescribers and pharmacists regarding black box warnings.

Method: A cross-sectional survey of self-reported behavior related to black box warnings was administered to prescribers and pharmacists across North Carolina between October 2010 and January 2011.

Results: A total of 867 pharmacists and prescribers completed the survey, including 715 pharmacists and 152 prescribers. Of the respondents, 54% were female and 92% described their ethnicity as Caucasian. Overall, pharmacists reported a greater change in behavior than did prescribers in relation to the presence of a boxed warning ($P < .01$). Pharmacists also demonstrated a significantly greater overall knowledge of boxed warnings compared to prescribers ($P < .01$). No differences in reported behavior or knowledge were observed between prescribers and pharmacists based on demographic factors.

Limitations: Solicitation through professional association mailing lists resulting in low response rates may impact findings.

Conclusion: Overall knowledge on information pertaining to boxed warnings was lacking. Impact in clinical practice due to the lack of understanding regarding boxed warnings may put patients at increased risk.

Keywords: Boxed warning, drug regulation, labeling knowledge, prescribing behavior, dispensing behavior

Introduction

Boxed warnings, frequently called “Black Box warnings”, are the strongest warning statements that the Food and Drug Administration (FDA) can require on a drug label.[1] These cautionary statements are placed predominately on the package insert and are called boxed warnings because of the actual box that surrounds the text. These warnings highlight potentially fatal or disabling adverse events that are typically identified from clinical data. However in the absence of clinical data, serious animal toxicity data may be utilized to support this cautionary labeling.[1] The FDA provides guidance for industry in conditions that may warrant a boxed warning. These conditions include life threatening adverse drug reactions and adverse drug reactions that can be prevented or reduced in frequency with appropriate drug use and monitoring, or with restricted distribution or use.[2] However, no clearly defined process or criteria exists for applying these standards to new drug applications or previously approved products.[3]³

The inclusion of a boxed warning, at approval or post-marketing, is designed to make health care providers aware of adverse events; however, according to the published literature, prescriber habits may or may not be affected by boxed warning recommendations.[4-13]⁴⁻¹³ The post-marketing addition of boxed warnings for antidepressants in pediatric and adolescent patients, and the use of antipsychotics in dementia patients caused a decline in the use of these drug classes for these specific populations.[7-13] Although some warnings result in a decrease in prescribing habits, residual inappropriate prescribing has been documented after the addition of some boxed warnings.[4-6,14-16] Lasser, et al.[4], reported that 1 in 10 ambulatory patients was prescribed at least 1 drug with a boxed warning, with approximately 7 in 1000 outpatients receiving a prescription for a drug that was in violation of the boxed warning. It is unclear if prescribers are unaware of the boxed warnings associated with these agents or utilize clinical judgment to assess a specific patient case.

The number of boxed warnings utilized may contribute to a lack of knowledge in healthcare providers. According to a historical review of the Physician’s Desk References published between 1975 and 2000, a total of 548 new chemical entities were approved. Throughout this time period, boxed warnings were added to 45 chemical entities (8.2%) after initial FDA approval.[2] While these data do not include boxed warnings that were part of the first approved labeling, it does indicate frequent addition of new warnings added after widespread use.

Objective

The purpose of this cross-sectional study was to examine the health care provider's knowledge and perception of boxed warnings and to determine if behavior is affected by these warnings. The self-reported awareness, perceptions, and impact of boxed warnings on prescribing and dispensing habits of providers was evaluated via an electronic survey.

Methods

In 2010, a questionnaire (Figure 1) was distributed electronically via Zoomerang to all registered pharmacists and prescribers in North Carolina (NC) to evaluate the main outcome of self reported behavior and knowledge related to boxed warnings. All completed surveys from October 26, 2010 to January 1, 2011 were utilized in data analysis. In order to detect at least a 10% difference between groups at 80% power with an alpha of .05 a sample of 540 participants was required. Pharmacist participants were recruited by email, via a list maintained by the NC Board of Pharmacy, and prescriber participants were recruited through a postcard delivered by the US postal services. The policy of the NC Board of Medicine prevented email contact with prescribers, but did allow the practice site mailing address to be purchased from a public database of all NC registered resident prescribers. The post card containing a URL linking prescribers to the survey was mailed to the address on file with the NC Board of Medicine. The post card described the study and invited prescribers to participate by visiting the link. Prescribers included physicians, physician assistants, and nurse practitioners. Study participants completed the online survey anonymously. Because the NC Board of Pharmacy does not disclose individual email addresses it was not possible to contact pharmacist non-respondents. Similarly, post cards sent out to prescribers did not contain a unique identifier; therefore, prescriber non-respondents could not be contacted. The decision to exclude a unique identifier was made by the research team in order to guarantee anonymity of the respondents but also prevented any utilization of incentives.

Data Sources

Several drug information databases were queried in June 2010 for drugs containing a boxed warning. These databases included Lexi-Comp, Facts and Comparisons, Clinical Pharmacology, Micromedex, and BlackBoxRX.com. All commercial products were then grouped by active chemical entity. Chemical entities no longer available in the United States were excluded. The remaining entities were then available for inclusion in the survey.

Survey instrument

The survey questions were developed by the research team based on a review of the available literature and professional experience of the pharmacists conducting the study. Questions were reviewed by colleagues for face validity, but pretesting was not performed.

The survey collected demographic information regarding gender, ethnicity, years in practice, and practice type for all participants (Figure 1). Pharmacists responded to a set of questions regarding their opinion of the influence which boxed warnings have on their practice. Prescribers responded to a similar set of questions regarding their opinion of the influence which boxed warnings have on their practice. All participants were asked to indicate how strongly they agree with each of three statements regarding the number of boxed warnings and the number of chemical entities with boxed warnings. For each of these statements participants could rate their opinion on a 5-point Likert scale. The scale consisted of the following: “Strongly Agree (5)”, “Agree (4)”, “Neutral (3)”, “Disagree (2)”, and “Strongly Disagree (1)”.

Additionally all participants were asked to rate their own awareness of boxed warnings using a 4-point Likert Scale consisting of the following options: “Extremely Aware (4)”, “Very Aware (3)”, “Somewhat Aware (2)”, and “Not at all Aware (1)”. All participants also answered a total of 14 knowledge questions that related to the actual number of chemical entities that possess boxed warnings, the type of event that warrants a drug or entity to receive a boxed warning, and the identification of common drugs that currently have a boxed warning.

Analysis

For behavioral questions related to the influence of boxed warnings (Figure 1), the Likert-scale scores for each participant were combined to create a composite score ranging between 3 and 15. The composite score was then compared between pharmacists and prescribers using an independent samples t-test. Each participant’s knowledge of boxed warnings was evaluated through responses to questions in Figure 1. Overall knowledge scores were calculated as the percent correct of the knowledge-based questions and compared between pharmacists and prescribers using an independent samples t-test. One-way analysis of variance (ANOVA) was used to evaluate differences regarding both behavior and knowledge among prescriber practice type and among pharmacist practice type. P-values lower than 0.05 were considered significant. A reliability analysis was conducted for the behavioral questions (see Fig. 1) and a Cronbach’s alpha of 0.87 was obtained

indicating sufficient internal reliability. Descriptive statistics are provided for self-reported awareness. All analyses were carried out using SPSS/PASW 18.0. This study was approved by the Institutional Review Board at Campbell University College of Pharmacy & Health Sciences.

Results

Invitations to participate were mailed to 26,153 prescribers with 49 post cards returned as undeliverable. Invitations to participate were emailed to 9,873 pharmacists with 297 returned as undeliverable. Of the pharmacists and prescribers solicited 1,126 accessed the survey. Of those who accessed the survey 77% responded to the survey and provided main outcome data related to behavior and knowledge pertaining to boxed warnings (715 Pharmacists and 152 prescribers) (Table 1). For the 867 respondents 54% were female, 46% were male, 92% described their ethnicity as Caucasian and 8% described themselves as non-Caucasian.

Prescribers and Pharmacists

An independent-samples *t* test was conducted to evaluate the difference in reported behavior between prescribers and pharmacists in relation to the presence of a boxed warning (Table 2). The test was significant, $t(865) = 4.65$, $P < .01$. Pharmacists on average reported a significantly greater change in behavior than did prescribers when dealing with products with a boxed warning (mean scores, 11.44 versus 10.34, respectively). An independent samples *t* test was conducted to evaluate the difference in overall mean score for knowledge between pharmacists and prescribers. Pharmacists demonstrated a significantly greater overall knowledge [$t(868) = 3.18$, $P < .01$] of boxed warnings than did prescribers (Table 3).

No differences in either reported behavior or knowledge were observed between prescribers and pharmacists based on demographic factors such as gender, ethnicity (white versus non-white), or location.

Among prescribers

A one-way ANOVA was conducted to evaluate the relationship between reported behavior related to boxed warnings and practice type of prescribers. The independent variable, practice type, consisted of four levels: Hospital – Inpatient,

140 Hospital – Emergency Medicine, Clinic, and Private Practice. The dependent variable was the composite score of reported
141 behavior related to boxed warnings. The ANOVA was significant, $F(3, 130) = 2.977$, $P = .03$.

142
143 Pair-wise comparisons demonstrated the differences among the means. Tukey post-hoc analysis confirmed that
144 prescribers who indicated their practice type to be Hospital – Emergency Medicine had a higher overall composite score
145 related to behavior than all other practice types included in the study. The 95% confidence intervals as well as the means
146 and standard deviations for the practice types are reported in Table 4.

147
148 A one-way ANOVA was conducted to evaluate the relationship between knowledge of boxed warnings and practice type
149 of prescribers. The independent variable, practice type, consisted of four levels: Hospital – Inpatient, Hospital –
150 Emergency Medicine, Clinic, and Private Practice. The dependent variable was the composite score for knowledge of
151 boxed warnings. The ANOVA was not significant. No differences were observed regarding reported behavior and
152 demographic factors such as ethnicity or gender.

153
154 *Among pharmacists*

155 A one-way ANOVA was conducted to evaluate the relationship between reported behavior related to boxed warnings and
156 practice type of pharmacists. The independent variable, practice type, consisted of seven levels: Academia, Community
157 Pharmacy – Independent, Community Pharmacy – Chain, Hospital, Clinic/Ambulatory Care, Long Term Care, Industry.
158 The dependent variable was the composite score of reported behavior related to boxed warnings. The ANOVA was not
159 significant.

160
161 A one-way ANOVA was conducted to evaluate the relationship between knowledge of boxed warnings and practice type
162 of pharmacists. The independent variable, practice type, consisted of seven levels: Academia, Community Pharmacy –
163 Independent, Community Pharmacy – Chain, Hospital, Clinic/Ambulatory Care, Long Term Care, Industry. The
164 dependent variable was the composite score for the knowledge questions. The ANOVA was not significant. No
165 differences were observed regarding reported behavior and demographic factors such as ethnicity or gender.

166
167

168 **Discussion**

169 Overall, knowledge of the justification and requirements for a boxed warning, number of chemical entities with a boxed
 170 warning, and individual agents that have a boxed warning was lacking. On the knowledge-based questions, prescribers
 171 scored on average 55% while pharmacists scored on average 59%, indicating a gap in knowledge for both groups.

172
 173 An incomplete understanding of criteria for the addition of a boxed warning to a chemical entity related to significant
 174 animal toxicity, even in the absence of human data, existed. Only 16% of survey respondents identified the animal
 175 toxicity as appropriate criteria for a boxed warning. However, the recent approval of liraglutide (Victoza – Novo Nordisk
 176 A/S) included a boxed warning for increased risk of thyroid C-Cell tumors that has only been observed in rodents.[17]
 177 The human risk, although the extent is currently unknown, was significant enough to warrant this labeling.

178
 179 Wang, et al.[18] evaluated the consistency of 3 commonly used databases in detecting an interaction in drugs
 180 contraindicated to be used concurrently. Each of the 3 interaction screening databases reported less than half of the
 181 expected interactions. The authors noted that the information regarding severity and evidence for contraindicated drug
 182 combinations, specifically addressed in boxed warnings, is quite variable between databases. Inconsistencies between
 183 databases and product package inserts have also been documented.[19] These inconsistencies may contribute to lack of
 184 knowledge since many prescribers or pharmacists typically have access to only one or two databases in daily practice. A
 185 contributor to this problem may be related to the lack of a FDA maintained list of all drugs/entities with a boxed warning.

186
 187 The two drugs in our survey that were most frequently identified as having a boxed warning were warfarin and fluoxetine
 188 (87% and 79%, respectively; Table 3). One reason for increased awareness for fluoxetine may be related to the intense
 189 lay media coverage of the announcement by the FDA to include a boxed warning due to the increased potential of suicide
 190 in children and adolescents on all antidepressants.[20] While lay media coverage of boxed warnings may be an avenue to
 191 communicate the risks, one study indicates that FDA and lay media reports of boxed warnings emphasized different
 192 information that is thought to be related to the different reasons for reporting the information.[21] These differences
 193 identified included an under reporting in the lay media of the generic names, research methods, clinical recommendations,
 194 and instruction to seek health care provider advice and an increased reliance on expert testimonials and personal stories

195 from patients.[21] A similar effect attributed to the lay press was documented in Moeller, et al.[22] for paroxetine and
 196 estrogen.
 197
 198 The effect caused by the existence of a boxed warning is mixed. In a study conducted by Lasser, et al.[4], 7 out of 1000
 199 outpatients received a prescription drug in violation of a boxed warning. However, an even higher rate of non-compliance
 200 with boxed warnings has been documented.[14,16,23,24] Of particular note are studies that examine the contraindicated
 201 use of metformin in patients with heart failure and/or renal failure due to the increased risk of lactic acidosis in this
 202 population.[14,25,26] Another area of documented non-compliance with a boxed warning occurred in the monitoring of
 203 patients taking lithium, carbamazepine, and valproate.[27] However, the rate of antidepressant use in children did
 204 diminish after the addition of a boxed warning to this class of drugs.[13] Also, changes to the use of antipsychotics in
 205 patients with dementia decreased after the addition of a boxed warning.[10] The reasons for non-compliance to a boxed
 206 warning or the absence of change in usage after the addition of a boxed warning are not known. Our data indicate that
 207 there may be a lack of knowledge of which agents have a particular type of boxed warning and this may be related to the
 208 large number of agents that include such a warning and database inconsistencies. These results suggest a need for
 209 additional black box education in schools of medicine and pharmacy in addition to professional continuing education
 210 focused on boxed warnings. Another effort to improve the overall knowledge of boxed warnings would be one central
 211 repository for all agents with boxed warnings.

212
 213

214 **Limitations**

215 The study is limited by the sample surveyed. Only prescribers and pharmacists in NC were recruited to participate. The
 216 inability to gain direct access to respondent names and email addresses prevented effective follow up for the majority of
 217 the population solicited; therefore, a follow up request and an evaluation of non-responders was not possible.
 218 Additionally, since the respondents were utilizing the internet to complete the survey, references could have been used to
 219 assist with the completion of the knowledge based questions. This could over-estimate the mean knowledge scores of
 220 participants. This study utilized self-reported data, which may not translate into actual practice behaviors. Formal
 221 pretesting was not performed on the survey tool. The actual wording of survey questions between prescribers and

pharmacists differed slightly, which may contribute to some of the differences observed. Lastly, the small proportion of prescriber respondents limits the power of the analysis – particularly for sub-group analysis.

Conclusion

Knowledge on justification and requirements for a boxed warning, number of chemical entities with a boxed warning, and individual agents that have a boxed warning was deficient with a mean score less than 60%. Low overall knowledge may indicate a barrier to communicating the purpose and reasoning for the addition of a boxed warning to a drug label. Impact in clinical practice due to the lack of understanding surrounding boxed warnings may put patients at an increased risk for serious adverse reactions.

REFERENCES

1. 21 Code of Federal Regulations Section 201.57(c)(1). 7/7/2010.
2. Center for Drug Evaluation and Research. Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products-content and format. Guidance for industry. Rockville, MD; US Department of Health and Human Services; January 2006.
3. Cook DM, Gurugubelli RK, Bero LA. Risk management policy and black-box warnings: A qualitative analysis of US FDA proceedings. *Drug Saf.* 2009;32:1057-1066.
4. Lasser KE, Seger DL, Yu DT, et al. Adherence to black box warnings for prescription medications in outpatients. *Arch Intern Med.* 2006;166:338-344.
5. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: Is the black box half empty or half full? *Pharmacoepidemiol Drug Saf.* 2006;15:369-386.
6. Zarowitz BJ. Black box warnings-implications in practice. *Geriatr Nurs.* 2008;29:402-409.
7. Dorsey ER, Rabbani A, Gallagher SA, et al. Impact of FDA black box advisory on antipsychotic medication use. *Arch Intern Med.* 2010;170:96-103.
8. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. *Arch Gen Psychiatry.* 2009;66:633-639.
9. Olfson M, Marcus SC, Druss BG. Effects of food and drug administration warnings on antidepressant use in a national sample. *Arch Gen Psychiatry.* 2008;65:94-101.
10. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999-2007. *Arch Gen Psychiatry.* 2011;68:190-197.
11. Hassanin H, Harbi A, Saif A, et al. Changes in antidepressant medications prescribing trends in children and adolescents in Hawai'i following the FDA black box warning. *Hawaii Med J.* 2010;69:17-19.

- 254 12. Cheung A, Sacks D, Dewa CS, et al. Pediatric prescribing practices and the FDA black-box warning on
255 antidepressants. *J Dev Behav Pediatr.* 2008;29:213-215.
- 256 13. Busch SH, Barry CL. Pediatric antidepressant use after the black-box warning. *Health Aff (Millwood).* 2009;28:724-
257 733.
- 258 14. Horlen C, Malone R, Bryant B, et al. Frequency of inappropriate metformin prescriptions. *JAMA.* 2002;287:2504-
259 2505.
- 260 15. Shah ND, Montori VM, Krumholz HM, et al. Responding to an FDA warning--geographic variation in the use of
261 rosiglitazone. *N Engl J Med.* 2010;363:2081-2084.
- 262 16. Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in medicare patients with heart failure.
263 *JAMA.* 2003;290:81-85.
- 264 17. VICTOZA (liraglutide [rDNA origin] injection). Product information. Princeton, NJ; Novo-Nordisk; August 2011.
- 265 18. Wang LM, Wong M, Lightwood JM, Cheng CM. Black box warning contraindicated comedications: Concordance
266 among three major drug interaction screening programs. *Ann Pharmacother.* 2010;44:28-34.
- 267 19. Cheng CM, Fu C, Guglielmo BJ, Auerbach AD. Boxed warning inconsistencies between drug information resources
268 and the prescribing information. *Am J Health Syst Pharm.* 2011;68:1626-1631.
- 269 20. FDA Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications.
270 Accessed at
271 [www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHe](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/PublicHealthAdvisories/ucm161679.htm)
272 [athcareProfessionals/PublicHealthAdvisories/ucm161679.htm](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/PublicHealthAdvisories/ucm161679.htm), August 15, 2011.
- 273 21. Yong PL, Bigman C, Flynn DN, et al. Messages about black-box warnings: A comparative analysis of reports from
274 the FDA and lay media in the US. *Drug Saf.* 2009;32:1147-1157.
- 275 22. Moeller KE, Shireman TI, Generali J, et al. Pharmacy students' knowledge of black box warnings. *Am J Pharm Educ.*
276 2010;74:1-5.
- 277 23. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. *JAMA.*
278 2001;286:831-833.
- 279 24. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: Impact of food and drug administration
280 regulatory action. *JAMA.* 2000;284:3036-3039.
- 281 25. Emslie-Smith AM, Boyle DI, Evans JM, et al. Contraindications to metformin therapy in patients with Type 2
282 diabetes: a population-based study of adherence to prescribing guidelines. *Diabet Med.* 2001;18:483-488.
- 283 26. Misbin RI, Green L, Stadel VB, et al. Lactic acidosis in patients with diabetes treated with metformin. *N Engl J*
284 *Med.* 1998;338:265-266.
- 285 27. Marcus SC, Olfson M, Pincus HA, et al. Therapeutic drug monitoring of mood stabilizers in medicaid patients with
286 bipolar disorder. *Am J Psychiatry.* 1999;156:1014-1018.
- 287

Table 1. Demographics

	Pharmacists	Prescribers	Overall
Gender [No. (%)]			
Women	415 (58)	50 (33)	465 (54)
Men	300 (42)	102 (67)	402 (46)
Race			
American Indian or Alaskan Native	7 (1)	1 (1)	8 (1)
Asian	29 (4)	7 (5)	36 (4)
Black or African American	14 (2)	10 (7)	24 (3)
Hispanic or Latino	0 (0)	4 (2)	4 (0)
Native Hawaiian or Other Pacific Islander	0 (0)	0 (0)	0 (0)
White (Caucasian)	665 (93)	130 (85)	795 (92)
Pharmacist Practice Site [No. (%)]			
Hospital	201 (28)		
Community-Independent	103 (14)		
Community-Chain	202 (28)		
Clinic/Ambulatory Care	52 (7)		
Industry	45 (6)		
Long Term Care	26 (4)		
Academia	17 (2)		
Did Not Report	69 (10)		
Prescriber Type [No. (%)]			
Physician		117 (77)	
Physician Assistant		34 (22)	
Nurse Practitioner		1 (1)	
Prescriber Practice Site [No. (%)]			
Hospital-Inpatient		23 (15)	
Hospital-Emergency Medicine		12 (8)	
Clinic		38 (25)	
Private Practice		61 (40)	
Other		18 (12)	

288

289

Table 2. Behavioral Questions Mean Scores

	Pharmacists Mean ± SD (# of respondents)	Prescribers Mean ± SD (# of respondents)	P-value
How many years have you been in practice?	18.99 ± 13.27 (715)	20.31 ± 11.69 (152)	.26
Additional caution is used when dispensing/recommending/prescribing a drug with a boxed warning. ^a	3.95 ± .89 (715)	4.24 ± .81 (152)	< .01
I perform a more intense drug utilization review when dispensing or recommending a drug with a boxed warning. ^a	3.76 ± .94 (715)	N/A	N/A
When I am aware, I avoid using drugs with boxed warnings ("black box" warnings). ^a	N/A	2.66 ± 1.14 (152)	N/A
I do not do anything different or additional when dispensing/ recommending/prescribing a drug with a boxed warning. ^a	3.79 ± 1.07 (715)	3.43 ± 1.14 (152)	<.01
Combined Score for Behavioral Questions	11.44 ± 2.67 (715)	10.34 ± 2.49 (152)	< .01
How would you rate your awareness of boxed warnings ("black box warnings")? ^b	2.62 ± .64 (670)	2.63 ± .67 (144)	.81
Too many chemical entities have boxed warnings. ^a	3.18 ± .97 (670)	3.15 ± 1.05 (144)	.78
An appropriate number of chemical entities have boxed warnings. ^a	2.98 ± .87 (670)	2.94 ± .83 (144)	.69
Not enough chemical entities have boxed warnings. ^a	2.54 ± .85 (670)	2.58 ± .90 (144)	.55

Note: a. Responses,5-point Likert Scale; b. Responses, 4-point Likert Scale

290
291

292

Table 3. Knowledge Results

	Pharmacists No. (%)	Prescribers No. (%)	P-value
Which of the following would warrant a boxed warning (“black box” warning)?			
--Death ^a	623 (93)	134 (93)	
--Serious Injury ^a	619 (92)	125 (87)	
--Animal toxicity in absence of clinical toxicity data ^a	104 (15)	25 (17)	
--Side Effects (Serious Adverse Events) that are present in >30% of the population	410 (61)	96 (67)	
--Unexplained side effects (Serious Adverse Events)	304 (45)	73 (51)	
How many chemical entities (active pharmaceutical ingredients) have boxed warnings (“black box” warnings)?			
0 to 100	271 (40)	37 (25)	
101 to 350	256 (38)	67 (47)	
351 to 500 ^a	96 (14)	22 (15)	
>500	48 (7)	18 (12)	
Which of the following drugs have a boxed warning (“black box” warning)?			
Alprazolam (Xanax-Pfizer US Pharmaceutical Group)	107 (16)	42 (29)	
Atorvastatin (Lipitor-Pfizer US Pharmaceutical Group)	237 (35)	49 (34)	
Fluoxetine (Prozac-Eli Lilly & Co.) ^a	536 (80)	107 (74)	
Ibuprofen (Motrin) ^a	285 (42)	51 (35)	
Lisinopril (Zestril-AstraZeneca, Prinivil-Merck Sharp & Dohme) ^a	218 (32)	58 (40)	
Nifedipine (Adalat CC-Schering-Plough Corporation, Procardia-Pfizer US Pharmaceutical Group)	151 (23)	43 (30)	
Tramadol (Ultram-Janssen)	210 (31)	62 (43)	
Warfarin (Coumadin-Bristol-Myers Squibb Company) ^a	598 (89)	113 (78)	
Overall Mean Percent Score ± SD	59 ± 13	56 ± 15	< .01
Total Complete Respondents	671 (82)	144 (18)	

^a Correct answer

293

294

Table 4. Comparison of Mean Composite Scores for Reported Behavior of Prescribers by Practice Type

Practice Type	<i>M</i>	<i>SD</i>	Mean Diff. (Hospital-Emergency)	95% <i>CI for Diff. of Means</i>
Hospital-Emergency	12.42	2.43		
Hospital-Inpatient	10.09	2.25	2.33 ^a	.02-4.64
Clinic	10.24	2.67	2.18 ^a	.03-4.33
Private Practice	10.16	2.47	2.26 ^a	.21-4.30

Note: ^aP < .05

Figure 1. Survey Instrument

See Attached .jpeg




Figure 1. Survey Instrument